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ABSTRACT
Objectives: The observed associations between
smoking and functional measures at older ages are
vulnerable to bias and confounding. Mendelian
randomisation (MR) uses genotype as an
instrumental variable to estimate unconfounded causal
associations. We conducted a meta-analysis of the
observational associations and implemented an MR
approach using the smoking-related single nucleotide
polymorphism rs16969968 to explore their causal
nature.
Setting: 9 British cohorts belonging to the HALCyon
collaboration.
Participants: Individual participant data on
N=26 692 individuals of European ancestry (N from
earliest phase analysed per study) of mean ages
50–79 years were available for inclusion in
observational meta-analyses of the primary outcomes.
Primary outcomes: Physical capability, cognitive
capability and cognitive decline. The smoking
exposures were cigarettes per day, current versus
ex-smoker, current versus never smoker and ever
versus never smoker.
Results: In observational analyses current and ever
smoking were generally associated with poorer
physical and cognitive capability. For example, current
smokers had a general fluid cognition score which
was 0.17 z-score units (95% CI −0.221 to −0.124)
lower than ex-smokers in cross-sectional analyses.
Current smokers had a walk speed which was 0.25
z-score units lower than never smokers (95% CI
−0.338 to −0.170). An MR instrumental variable
approach for current versus ex-smoker and number
of cigarettes smoked per day produced CIs which
neither confirmed nor refuted the observational
estimates. The number of genetic associations
stratified by smoking status were consistent with
type I error.
Conclusions: Our observational analysis supports
the hypothesis that smoking is detrimental to physical
and cognitive capability. Further studies are needed
for a suitably powered MR approach.
INTRODUCTION
Epidemiological studies have been con-
ducted to explore the associations between
smoking and physical and cognitive capabil-
ity in mid to later life, generally concluding
that smoking is associated with worse cap-
ability outcomes.1–8 Physical and cognitive
capability, otherwise known as the physical
and intellectual tasks of daily living, are
often used as markers of ageing having
been consistently shown to be associated
with survival and onset of disease and dis-
ability. For example, a recent meta-analysis
of over 30 studies showed that poorer
objective physical capability is associated
with higher mortality rates.9 Smoking is a
modiﬁable behaviour and understanding
the extent to which it inﬂuences biological
Strengths and limitations of this study
▪ Using individual participant data from nine UK
cohorts of ageing individuals, this study
meta-analyses the associations between smoking
and physical and cognitive capability in later life.
▪ We consider cognitive and physical capability, in
addition to cognitive capability decline.
▪ We derive a score for general fluid cognition and
include this in cross-sectional analyses.
▪ We use the rs16969968 single nucleotide poly-
morphism, which associates with nicotine
dependence, in a Mendelian randomisation (MR)
to explore the causality of the observational
associations.
▪ While our study has demonstrated the feasibility
of using an MR approach to understand the
association of smoking with ageing outcomes, it
has demonstrated that a larger sample size is
required for a suitably powered analysis.
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ageing is crucial given the burden of morbidity in
today’s ageing populations.
The associations between smoking and markers of
ageing are likely to be confounded (or mediated) by
factors such as socioeconomic position (SEP), body mass
index, health status and prior IQ. Although studies have
adjusted for these factors, residual confounding and
bias may have affected the interpretation of results.
Mendelian randomisation (MR) uses genotype as an
instrumental variable (IV) to estimate the causal effect
of an exposure on an outcome free of confounding and
reverse causation bias.10 11 If genotype is associated with
the exposure under consideration and is not associated
with the confounders of the observational association,
nor directly with the outcome of interest, it may be used
to conduct an IV analysis to generate a causal estimate
of the observational association. This can be implemen-
ted, for example, using a two-stage approach where the
predicted exposure based on genotype is used to
measure the association with the outcome. Associations
of genotype with the outcome in different strata of the
exposure can also contest or support the causality of the
observational association. If a genetic association is
observed in exposed individuals and not in unexposed
individuals, this supports a causal observational associ-
ation. The minor allele of the rs16969968 single nucleo-
tide polymorphism (SNP) in the CHRNA5 gene has
been consistently associated with increased nicotine
dependence,12 therefore providing a potential instru-
ment for MR analyses of the effects of smoking.
Harnessing the availability of data across cohorts
belonging to the HALCyon collaboration,13 we have con-
ducted a meta-analysis of smoking and physical and cog-
nitive capability using individual participant data (IPD)
from middle-aged to older individuals in the UK. Given
the known associations between rs16969968 and nicotine
dependence, we explored the associations between this
SNP and our ageing outcomes in different smoking
classes to supplement the observational associations. We
considered that if associations are observed in current or
ever smokers but not in never smokers, this provides evi-
dence to support causality. We implemented instrumen-
tal variable regression to generate IV estimates for the
true causal associations of smoking with continuous
physical and cognitive capability measures. Our aim was
to examine whether the observational associations are
consistent with estimates obtained using an MR
approach.
METHOD
IPD was meta-analysed across nine cohorts belonging to
the HALCyon collaboration. These included the Boyd
Orr Cohort (BO), the Caerphilly Prospective Study
(CaPS), the English Longitudinal Study of Ageing
(ELSA), the Hertfordshire Ageing Study (HAS), the
Hertfordshire Cohort Study (HCS), the Lothian Birth
Cohort 1921 (LBC1921), the National Child
Development Study (NCDS), the MRC National Survey
of Health and Development (NSHD) and the Whitehall
II Study (WHII). Further information about the cohorts
is provided in previous HALCyon publications.14
Outcome measures
Physical capability was assessed using the objective mea-
sures grip strength, chair rise speed, inability to balance
on one leg for 5 s with eyes open, walking speed and
timed get up and go (TUG) speed. Cognitive capability
measures included tests of crystallised intelligence
(National Adult Reading Test (NART) and Mill Hill)
and ﬂuid intelligence (Alice-Heim 4-I test (AH4),
semantic ﬂuency, phonemic ﬂuency, search speed, word
recall, four choice reaction time (FCRT), logical
memory and Raven’s Progressive Matrices). Crystallised
intelligence measures knowledge accumulated across the
life course like vocabulary and captures premorbid IQ,
while ﬂuid intelligence measures problem-solving
skills.15 Cognitive decline was calculated by taking the
percentage change in continuous cognitive measure
between the baseline wave and the last available wave.
This was then converted to the percentage change per
year using the age difference between waves. Individuals
were categorised into a binary variable of the top 25%
of decliners versus others in each cohort. This approach
is similar to previous studies.16 17 We used factor analysis
to derive a general ﬂuid (Gf) cognitive ability score and
included this in the cross-sectional analyses.
Smoking behaviour
Participants were classiﬁed at the time of baseline cap-
ability assessment as current, ex or never smokers. A
‘smoker’ was deﬁned as an individual who smoked pipes,
cigars, manufactured cigarettes or hand-rolled cigarettes,
if this information was available. For current smokers, we
additionally analysed number of cigarettes smoked per
day (CPD). Where possible this was restricted to manu-
factured cigarettes to maintain consistency in tobacco
quantities. Individuals who were occasional smokers
(smokes less than 1 CPD or does not smoke daily but
does smoke occasionally) were re-coded as smoking 0
CPD. In Boyd Orr, we estimated CPD by taking the
median of intervals of cigarettes smoked per day.
Genetic analyses
We genotyped rs16969968 across cohorts where this
was not previously available. Rs1051730 was substituted
into analyses where available and when rs16969968
was unavailable (see online supplementary table S1).
These two SNPs are highly correlated and thus
interchangeable.12
Covariates
We selected a range of covariates a priori. These were
sex, age (continuous), socioeconomic position obtained
from the earliest wave of outcome assessment (the
Registrar-General’s Social Class, RGSC), body mass
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index (BMI), height and disease status (history of dia-
betes, stroke or heart disease: see online supplementary
table S2). BMI, height and disease status were derived
using data from the same wave as each outcome
measure if available unless the outcome was a decline
measure in which case the covariates were taken from
the baseline wave. Age, sex and SEP were included as
potential confounders of the observational associations
of smoking and physical and cognitive capability. Disease
history was included to examine the extent of mediation
of smoking effects via diabetes, stroke and heart disease.
BMI may confound and mediate the association of
smoking and physical capability, while height is strongly
correlated with physical capability outcomes.
Further information on the genotyping and the deriv-
ation and harmonisation of the exposures, covariates and
outcomes is provided in online supplementary material.
Statistical analysis
All analyses were conducted using Stata 13.1.18 Known
ethnic outliers were excluded from the analysis (self-
reported non-European ancestry or previously detected
from genome-wide data), as were related individuals. For
harmonisation continuous outcome measures were stan-
dardised within cohorts using all data available. Logistic
regression was implemented for analyses of binary out-
comes and linear regression for continuous outcomes.
Four choice reaction time was inverse transformed
and search speed was natural log transformed to
improve normality. A score for Gf was derived in several
cohorts using the -factor- command in Stata18 using the
pcf option and imposing one factor, to supplement
cross-sectional analyses.
Observational analyses assessed the associations
between CPD or smoking status (current vs ex, current
vs never or ever vs never smoker) and each of the phys-
ical and cognitive capability measures. Three models
were run for physical capability adjusted for (1) age,
SEP and sex (2) age, SEP, sex and disease status (3) age,
SEP, sex, disease status, height and BMI. Models (1) and
(2) were run for the cognitive outcomes.
The rs16969968 genotype was coded additively as 0, 1
or 2 minor alleles. The associations between genotype
and smoking behaviour were calculated using linear or
logistic regression. The associations between genotype
and physical and cognitive capability were calculated in
current, never and ever smokers to test for both plei-
otropy and whether an association was observed in
current and ever but not never smokers. All genetic asso-
ciations were adjusted for age and sex.
For the smoking exposures which correlated with
genotype (cigarettes per day and current vs ex smoking)
and for the continuous outcomes which associated with
these smoking exposures, we performed IV estimation
using the two-stage least squares (2SLS) estimator and
compared the observational estimates with the IV esti-
mates. The IV assumptions, that can be checked using
observational data, were checked by testing the
unadjusted associations between genotype and the
covariates.
All associations were analysed within cohorts and the
effect estimates meta-analysed using a random effects
two-stage approach.19 20 The observational analyses
included all individuals with data available on the expo-
sures and outcomes of interest. Secondary models were
restricted to individuals who had relevant covariates
available. The genetic and IV analyses on the associa-
tions between genotype and cognitive and physical cap-
ability were conducted on a subset of the observational
sample with genotype data. The associations between
genotype and smoking behaviour or covariates were
examined in all individuals with data available.
RESULTS
The observational and genetic samples are characterised
in table 1 and online supplementary tables S3–5. The
mean age in the observational analysis was 50–79 years
and the majority of studies had similar numbers of men
and women. The total sample size taking the earliest
wave of outcome assessment was 26 692. As shown in
table 2, each of the physical capability outcomes was
associated with at least one comparison of smoking
status. In particular, current compared to never smoker
status resulted in a decrease in walking or TUG speed of
between 0.23 and 0.29 z-scores (p<0.0001). Across out-
comes and models, the effect estimates generally suggest
that being a current or an ever smoker was associated
with worse physical capability compared to never
smokers. Adjustment for BMI and height often resulted
in an increased magnitude of effect on physical capabil-
ity for the smoking exposures. Heterogeneity statistics
are provided in the Supplement.
Current compared to ex or never smokers performed
more poorly across all cross-sectional cognitive outcomes
tested for both models with the exception of phonemic
ﬂuency and the single cohort analyses (table 3, see
online supplementary table S6). An extra cigarette per
Table 1 Age and sex by cohort study
Cohort
Mean age in
years (SE)
Percentage
female
Total sample
size, n
BO 69.64 (0.25) 55.56 279
CaPS 61.77 (0.10) 0 1831
ELSA 66.01 (0.13) 54.56 5425
HAS 67.39 (0.09) 35.85 636
HCS 66.13 (0.05) 47.84 2803
LBC 79.06 (0.02) 57.38 542
NCDS 50 (NA) 50.63 7652
NSHD 53.45 (0.00) 50.9 2949
WHII 55.39 (0.09) 26.56 4575
TOTAL 26 692
Numbers based on all individuals with age, sex, smoking status,
socioeconomic position (SEP) and at least one outcome measure
at the earliest phase analysed. Numbers based on grip strength
analysis for HCS.
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Table 2 Observational estimates for the associations between smoking and physical capabilities
Outcome Model† Cigarette per day‡ Current vs ex-smoker Current vs never smoker Ever vs never smoker
Regression coefficient (95% CI)
Grip strength M1 0.000 (−0.003 to 0.003) −0.049** (−0.085 to −0.014) −0.017 (−0.077 to 0.043) −0.002 (−0.045 to 0.041)
M2 0.001 (−0.003 to 0.004) −0.054** (−0.088 to −0.019) −0.012 (−0.069 to 0.045) 0.006 (−0.034 to 0.047)
M3 0.001 (−0.003 to 0.004) −0.026 (−0.060 to 0.008) −0.006 (−0.051 to 0.040) −0.001 (−0.040 to 0.038)
Chair rise speed M1 −0.004 (−0.010 to 0.001) −0.111** (−0.190 to −0.032) −0.150*** (−0.233 to −0.067) −0.061** (−0.102 to −0.020)
M2 −0.004 (−0.010 to 0.002) −0.115** (−0.188 to −0.043) −0.152*** (−0.242 to −0.062) −0.059* (−0.108 to −0.010)
M3 −0.002 (−0.008 to 0.004) −0.152**** (−0.224 to −0.079) −0.188*** (−0.285 to −0.091) −0.052* (−0.095 to −0.009)
Walk speed M1 −0.006 (−0.016 to 0.005) −0.129* (−0.242 to −0.016) −0.254**** (−0.338 to −0.170) −0.136**** (−0.171 to −0.102)
M2 −0.006 (−0.015 to 0.002) −0.142* (−0.250 to −0.033) −0.247**** (−0.325 to −0.168) −0.124**** (−0.159 to −0.089)
M3 −0.001 (−0.013 to 0.010) −0.185** (−0.304 to −0.066) −0.266**** (−0.373 to −0.159) −0.110**** (−0.144 to −0.075)
TUG speed M1 0.000 (−0.010 to 0.011) −0.075 (−0.161 to 0.011) −0.233**** (−0.323 to −0.144) −0.138** (−0.234 to −0.042)
M2 0.001 (−0.009 to 0.012) −0.102* (−0.186 to −0.017) −0.236**** (−0.331 to −0.142) −0.123* (−0.217 to −0.029)
M3 0.007 (−0.007 to 0.021) −0.166**** (−0.249 to −0.082) −0.290**** (−0.383 to −0.197) −0.132*** (−0.205 to −0.060)
OR (95% CI)
Inability to balance on one leg for
5 s
M1 1.015 (0.994 to 1.036) 1.125 (0.937 to 1.351) 1.210 (0.948 to 1.543) 1.092 (0.957 to 1.246)
M2 1.013 (0.992 to 1.035) 1.155 (0.958 to 1.392) 1.232* (1.000 to 1.516) 1.064 (0.930 to 1.217)
M3 1.007 (0.985 to 1.029) 1.361** (1.120 to 1.655) 1.415** (1.106 to 1.811) 1.074 (0.934 to 1.236)
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Models: (M1) age, sex and SEP adjusted, (M2) M1 + disease adjusted, (M3) M2 + height, BMI adjusted.
‡Association is for 1 CPD for comparison with genotypic analysis.
BMI, body mass index; CPD, cigarettes smoked per day; SEP, socioeconomic position; TUG, timed get up and go.
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Table 3 Observational estimates for the associations between smoking and cognitive capabilities
Regression coefficient (95% CI)
Outcome Model† Cigarette per day Current vs ex-smoker Current vs never smoker Ever vs never smoker
Crystallised measures
Mill Hill M1 −0.003 (−0.012 to 0.005) −0.140*** (−0.216 to −0.063) −0.192**** (−0.266 to −0.117) −0.092*** (−0.142 to −0.043)
M2 −0.004 (−0.013 to 0.005) −0.146*** (−0.223 to −0.070) −0.194**** (−0.269 to −0.119) −0.090*** (−0.140 to −0.040)
NART M1 −0.004 (−0.010 to 0.001) −0.174**** (−0.261 to −0.088) −0.159** (−0.262 to −0.056) −0.041 (−0.097 to 0.016)
M2 −0.004 (−0.010 to 0.002) −0.194**** (−0.265 to −0.123) −0.142* (−0.260 to −0.023) −0.028 (−0.086 to 0.030)
Fluid measures
Gf M1 −0.002 (−0.011 to 0.007) −0.173**** (−0.221 to −0.124) −0.147**** (−0.205 to −0.088) −0.036* (−0.067 to −0.006)
M2 −0.002 (−0.011 to 0.007) −0.178**** (−0.228 to −0.129) −0.137**** (−0.199 to −0.074) −0.029 (−0.059 to 0.002)
AH4 M1 0.000 (−0.008 to 0.009) −0.139**** (−0.195 to −0.082) −0.135**** (−0.196 to −0.073) −0.047* (−0.090 to −0.003)
M2 0.000 (−0.009 to 0.009) −0.148**** (−0.206 to −0.090) −0.129**** (−0.192 to −0.065) −0.040 (−0.084 to 0.004)
Semantic fluency M1 −0.002 (−0.008 to 0.003) −0.139**** (−0.175 to −0.104) −0.105*** (−0.162 to −0.047) −0.019 (−0.059 to 0.021)
M2 −0.002 (−0.007 to 0.003) −0.136**** (−0.172 to −0.100) −0.095** (−0.155 to −0.035) −0.012 (−0.053 to 0.029)
Phonemic fluency M1 −0.005 (−0.015 to 0.006) −0.028 (−0.378 to 0.322) 0.041 (−0.289 to 0.372) 0.031 (−0.022 to 0.084)
M2 −0.005 (−0.015 to 0.005) −0.063 (−0.355 to 0.228) 0.056 (−0.295 to 0.407) 0.037 (−0.016 to 0.091)
Search speed‡ M1 −0.005* (−0.009 to −0.001) −0.122*** (−0.188 to −0.057) −0.148** (−0.239 to −0.057) −0.059** (−0.099 to −0.019)
M2 −0.006** (−0.010 to −0.002) −0.122*** (−0.192 to −0.052) −0.142** (−0.232 to −0.051) −0.054** (−0.091 to −0.016)
Word recall M1 −0.005 (−0.010 to 0.000) −0.144*** (−0.222 to −0.067) −0.138**** (−0.192 to −0.083) −0.044*** (−0.071 to −0.018)
M2 −0.005 (−0.010 to 0.000) −0.143*** (−0.222 to −0.064) −0.134**** (−0.191 to −0.078) −0.042** (−0.069 to −0.016)
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Models: (M1) age, sex and SEP adjusted, (M2) M1 + disease adjusted.
‡Natural log transformed.
AH4, Alice-Heim 4-I test; GF, general fluid; NART, National Adult Reading Test; SEP, socioeconomic position.
North
T-L,etal.BM
J
Open
2015;5:e008393.doi:10.1136/bm
jopen-2015-008393
5
O
p
e
n
A
c
c
e
s
s
day was associated with a slower search speed (p<0.01 in
model 2) and there was a trend towards poorer word
recall ability.
There were fewer associations apparent between
smoking behaviour and cognitive decline (see online
supplementary tables S7 and 8). Notably, current com-
pared to ex-smokers were more likely to be in the quar-
tile of greatest decliners in AH4 score, word recall
ability, search speed and FCRT. Current smokers experi-
enced worse decline than never smokers in word recall
and FCRT, while ever smokers declined faster on the
Raven’s Progressive Matrices than never smokers.
Adjustment for disease status had a small inﬂuence on
the effect sizes for cognitive outcomes in general.
Instrumental variable analysis
The association between rs16969968 and smoking behav-
iour is summarised in ﬁgures 1 and 2 and online supple-
mentary ﬁgures 1 and 2. Each minor allele predicts
approximately 1 extra cigarette smoked per day
(ﬁgure 1). The F statistic21 for the strength of the associ-
ation between each minor allele and CPD, obtained
from the partial R2 value from the ﬁrst stage of the age
and sex-adjusted 2SLS regression of CPD and log-
transformed search speed, was 3.51 in NSHD, 7.18 in
ELSA and 13.64 in NCDS. We also observed an associ-
ation between each extra minor allele and an increased
odds of being a current compared with an ex-smoker
(ﬁgure 2, p=0.02). There was some evidence of an asso-
ciation between the SNP and being an ever versus a
never smoker (see online supplementary ﬁgure 1,
decreased odds of ever smoker p=0.05), but no evidence
for an association with being a current versus a never
smoker (see online supplementary ﬁgure 2).
There was no evidence for an association between
rs16969968 and the covariates, although the age distri-
bution was non-normal (see online supplementary table
S9). We tested the association between rs16969968 and
each outcome in current, never and in ever smokers
(table 4, see online supplementary table S10). We
observed an association between the smoking suscepti-
bility allele and increased odds of being in the top 25%
of decliners for FCRT in current smokers (see online
supplementary table S10). In never smokers, we
observed an association between the same allele and
poorer search speed.
Given the strong association between rs16969968 and
CPD, and the weaker association with this variant and
current versus ex-smoker status, we progressed all obser-
vational associations for these exposures (arbitrary
threshold of p<0.05) to an IV analysis. The results are
described in table 5 (and see online supplementary
table S11). The CIs from the observational estimates fall
within the CIs from the IV estimates. The IV results,
however, are not informative about the causality of the
observational associations because the IV CIs are wide.
Figure 1 Meta-analysis of minor
allele—cigarettes smoked per day
association.
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DISCUSSION
This study has conﬁrmed that smoking, whether it be
current smoking or ever smoking, is associated with
poorer grip strength, chair rise speed, TUG/walk speed
and balance ability in a combined analysis of UK ageing
cohorts. In addition, smoking was associated with poorer
cognition across eight different cognitive tests and ﬁve
measures of cognitive decline. The large sample size that
HALCyon affords reveals some novel associations that, to
our knowledge, have not been reported before. Notably,
an association between cigarettes smoked per day and
poorer search speed in current smokers. In addition, the
high precision of the observational effect-estimates from
this analysis are reﬂected in the narrow CIs. However,
some of the observational association is due to residual
confounding, as demonstrated by the association
observed between smoking and measures of crystallised
cognition which should be fairly robust to adverse envir-
onmental factors acting from young adulthood and later.
This study has analysed data across a wide range of
cohorts from different geographical locations and with
different age ranges. Many of the results should thus be
generalisable to British individuals of European ancestry
of middle to older ages. As with any cohort study,
however, there may have been a healthy survivor effect
and particularly the analysis of ever smokers may be
applicable only to healthy smokers. All cohorts, however,
demonstrated genotype frequencies within Hardy-
Weinberg Equilibrium (HWE).22 The HWE p value for
all cohorts individually was >0.3 with the exception of
LBC1921 (p=0.08), while the collective p value for all
cohorts combined was 0.73 (see online supplementary
table S3). If the analysis is indeed conﬁned to healthy
smokers, then the negative effect of smoking on physical
and cognitive capability could be biased downwards here.
Adjustment for height and BMI in the physical cap-
ability observational models often resulted in an
increased magnitude of effect of smoking status on
outcome. BMI could both confound and mediate the
association of smoking with physical capability, so the
causal relationships are likely to be complex. BMI, in
addition to disease status, could also be a collider,
whereby covariate adjustment induces a false association
between exposure and outcome. Such issues are the
primary motivation for conducting an MR. Adjustment
for history of disease did not substantially alter the effect
estimates in general. While this could suggest that the
diseases considered are not on the causal pathway
between smoking and outcome, the lack of attenuation
could be because these variables have not adequately
captured disease history or because they were derived
using history of ever having these conditions and thus
do not capture smoking-induced incident disease.
The genetic analyses detected an association between
rs16969968 and poorer search speed in never smokers.
We caution that this could be a false positive due to
Figure 2 Meta-analysis of minor
allele—current versus ex-smoker
association.
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Table 4 Associations between rs16969968 and outcomes stratified by smoking status
Outcome category Outcome Current smokers Never smokers Ever smokers
Regression coefficient (95% CI)
Physical capability Grip strength 0.008 (−0.044 to 0.061) 0.016 (−0.030 to 0.062) −0.015 (−0.037 to 0.008)
Chair rise speed 0.003 (−0.123 to 0.130) 0.000 (−0.078 to 0.079) −0.002 (−0.048 to 0.044)
Walk speed 0.049 (−0.122 to 0.220) 0.026 (−0.015 to 0.068) 0.002 (−0.033 to 0.038)
TUG speed −0.043 (−0.154 to 0.067) −0.015 (−0.083 to 0.054) −0.024 (−0.077 to 0.029)
Cognitive capability Mill Hill 0.062 (−0.058 to 0.182) −0.031 (−0.096 to 0.034) −0.042 (−0.214 to 0.129)
NART 0.020 (−0.075 to 0.116) −0.009 (−0.098 to 0.080) −0.004 (−0.058 to 0.051)
Gf 0.048 (−0.011 to 0.108) −0.035 (−0.074 to 0.004) 0.016 (−0.015 to 0.047)
AH4 0.024 (−0.069 to 0.118) −0.040 (−0.102 to 0.021) 0.013 (−0.038 to 0.064)
Semantic fluency 0.028 (−0.038 to 0.094) −0.013 (−0.048 to 0.022) 0.014 (−0.014 to 0.042)
Phonemic fluency −0.033 (−0.160 to 0.094) −0.018 (−0.085 to 0.048) −0.126 (−0.398 to 0.145)
Search speed† 0.024 (−0.045 to 0.093) −0.060* (−0.116 to −0.003) 0.005 (−0.028 to 0.038)
Word recall 0.045 (−0.009 to 0.099) −0.018 (−0.058 to 0.023) 0.015 (−0.014 to 0.044)
OR (95% CI)
Physical capability Inability to balance on one leg for 5 s 1.010 (0.732 to 1.394) 1.052 (0.896 to 1.236) 0.921 (0.817 to 1.038)
Cognitive capability decline Mill Hill 0.535 (0.063 to 4.559) 0.943 (0.798 to 1.114) 0.935 (0.802 to 1.089)
NART 1.016 (0.678 to 1.522)‡ 0.878 (0.559 to 1.379) 1.085 (0.848 to 1.388)
AH4 1.007 (0.786 to 1.289) 1.127 (0.955 to 1.329) 0.925 (0.807 to 1.060)
Semantic fluency 0.975 (0.748 to 1.271) 1.243 (0.926 to 1.670) 0.984 (0.891 to 1.086)
Phonemic fluency 1.003 (0.735 to 1.369)§ 1.097 (0.807 to 1.492) 1.163 (0.565 to 2.393)
Word recall 0.999 (0.832 to 1.201) 1.024 (0.913 to 1.149) 0.978 (0.890 to 1.074)
Models adjusted for age and sex.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Natural log transformed.
‡Analysis in CAPS only.
§Analysis in WHII only.
AH4, Alice-Heim 4-I test; Gf, general fluid; NART, National Adult Reading Test; TUG, timed get up and go.
8
North
T-L,etal.BM
J
Open
2015;5:e008393.doi:10.1136/bm
jopen-2015-008393
O
p
e
n
A
c
c
e
s
s
multiple testing. Of the seven cross-sectional cognitive
outcomes considered in table 4 and excluding the
current smokers, there were 14 independent tests.
The Bonferroni corrected p value is 0.004. However, the
result is in support of a hypothesis described by
Winterer et al23 that suggested the mediation of the
effect of the rs16969968 risk allele on greater nicotine
dependence to be via poorer cognition. If the cognitive
outcomes under consideration are on the causal
pathway between the SNP and nicotine dependence,
this violates the MR assumptions. In general, however,
we conclude that the rs16969968 variant does not exert
a direct effect on the outcomes that is large enough to
be detectable in our sample, owing to the lack of an
association in never smokers. The trend towards
improved word recall ability per minor allele in current
smokers complements a study on elderly Taiwanese indi-
viduals which found a protective effect of smoking on
cognitive function.24
The association in a single cohort (CaPS) between
current versus ex-smoker status and greater odds of
decline in FCRT score complements the positive associ-
ation of the minor allele of rs16969968 with greater
odds of FCRT decline in current smokers but not never
smokers. If this association is not spurious then it sup-
ports the causality of the observational association
between continuing smoking and a decline in reaction
ability over time.
The IV CIs did not refute the observational estimates.
Our approach is a suitable framework for future studies
with larger sample sizes. Taking the predictive utility of
rs16969968 for CPD as an example, each additional
allele predicts one extra cigarette smoked each day and
accounts for approximately 1% of the variance in CPD
among current smokers. Using mRnd,25 an online
sample size calculation tool for MR, and taking a mean
CPD of 14 and a variance in CPD of 81 (as per ELSA
current smokers), genetic association testing in current
smokers would require 961 individuals to detect an
effect of 1 extra CPD on outcome of 0.1 z-score units.
This sample size, which assumes 80% power and a 5%
type I error rate, was achieved for several of the out-
comes in HALCyon (see online supplementary table
S5). However, the observed point estimate for smoking 1
extra CPD on log-transformed search speed was −0.005
z-score units, which would require a sample size of
386 815 current smokers in a 2SLS IV analysis. This
demonstrates that an MR approach in HALCyon with
CPD as the exposure is underpowered to detect effect
sizes comparable to the observational associations, but is
powered to detect moderate effect sizes. The lack of
associations observed in this MR analysis suggest that the
true causal effect sizes are unlikely to be moderate and
are more likely to be of small magnitude. A sample size
of nearly 400 000 current smokers could only be
achieved via meta-analysis of consortia and inclusion of
large studies such as the UK BIOBANK study (http://
www.ukbiobank.ac.uk/).
While the association between the minor allele of
rs16969968 and smoking an extra cigarette per day
reported here is in agreement with the literature,12 our
ﬁnding of a decreased odds of being an ever smoker
with each extra minor allele is likely to be spurious. Lips
et al26 found no association of smoking initiation with
this SNP while Sherva et al27 found an association
between the minor allele and increased odds of being a
current versus a never smoker. In our analysis, the SNP
appears to be associated with a decreased odds of initiat-
ing smoking but also with a decreased odds of quitting
once smoking is initiated. Although there has been
some evidence of an association between this variant
and quitting ability in previous studies even after adjust-
ment for smoking quantity,28 29 this latter association has
not been consistently replicated.26 A recent MR study
Table 5 Comparison of observational with instrumental variable estimates
Observational association of interest Observational estimate, βO†
(95% CI)
IV estimate, βIV
(95% CI)Smoking behaviour Outcome
Cigarettes per day Search speed‡ −0.005* (−0.009 to −0.001) 0.017 (−0.041 to 0.075)
Current vs ex-smoker Grip strength −0.049** (−0.085 to −0.014) −0.417 (−1.344 to 0.510)
Walk speed −0.129* (−0.242 to −0.016) −0.411 (−2.008 to 1.186)
TUG speedM3 −0.166**** (−0.249 to −0.082) −0.941 (−3.937 to 2.055)
Chair rise speed −0.111** (−0.190 to −0.032) −0.039 (−1.398 to 1.319)
NART −0.174**** (−0.261 to −0.088) −1.236 (−8.711 to 6.238)
Mill Hill −0.140*** (−0.216 to −0.063) −2.785 (−7.107 to 1.537)
Gf −0.173**** (−0.221 to −0.124) 0.029 (−1.394 to 1.453)
Semantic fluency −0.139**** (−0.175 to −0.104) −0.154 (−1.571 to 1.263)
AH4 −0.139**** (−0.195 to −0.082) −1.575 (−4.707 to 1.556)
Word recall −0.144*** (−0.222 to −0.067) 0.247 (−1.045 to 1.538)
Search speed‡ −0.122*** (−0.188 to −0.057) 0.312 (−1.121 to 1.744)
As explained in the methods, sample used to calculate observed and IV estimates differs according to the availability of variables.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Observational estimates are model M1 unless stated otherwise.
‡Natural log transformed.
AH4, Alice-Heim 4-I test; Gf, general fluid; IV, instrumental variable; NART, National Adult Reading Test; TUG, timed get up and go.
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which included several of the HALCyon cohorts
reported a similar per allele OR30 for current versus
ex-smoker but no association for ever versus never. As
discussed above, the lack of a genetic association with
current versus never smoker status that we report here
adds to a body of literature reporting conﬂicting associa-
tions of this SNP with smoking initiation.12 27
The F statistics extracted from the 2SLS IV analysis of
CPD and natural log-transformed search speed suggest
that rs16969968 could suffer from weak instrument bias.
It has been suggested21 that pooling the data from the
individual studies and conducting an IPD MR can
reduce this bias. A suitably powered IV analysis of CPD
and search speed could explore these approaches
further. However, it has also been noted30 31 that IV esti-
mates generated using CPD as the exposure variable and
rs16969968 as the genetic instrument will be biased
because this SNP predicts other measures of tobacco
exposure independently of CPD, thus violating the statis-
tical assumptions of MR. In light of this, future MR
studies of CPD and physical and cognitive capability
should focus on examination of the genetic associations
in current and never smokers, rather than on generating
precise IV estimates of the true observational association.
Such an approach, however, may also be weakened if
ever smokers incorrectly report themselves to be never
smokers or current smokers do not report the true levels
of cigarettes smoked per day. Objective measures of
tobacco exposure like cotinine levels avoid some of the
problems of inaccurate self-reporting and it has been
shown that rs16969968 is a strong predictor of cotinine
independent of CPD.32 This biomarker, however, was
not available across the HALCyon studies for
meta-analysis. As recently highlighted,30 a further limita-
tion of MR is that collider bias can occur when we strat-
ify the genetic associations by smoking status because
rs16969968 is associated with smoking status. Given the
few genetic associations observed in table 4 and online
supplementary table S10, which are consistent with type
I error, collider bias is unlikely to have affected this
analysis.
Our study could be extended in several other respects.
The observational analyses could consider change in
smoking behaviour over time3 33 and, as data becomes
available, decline in physical capability. Further research
using a longitudinal approach with repeat data is
needed in the future. In addition, further covariates
could be incorporated into the observational models.
The association of smoking with physical and cognitive
capability is likely to be confounded by other factors
such as alcohol intake, IQ and stress.
Previous studies of smaller sample size than ours have
been successful at implementing an IV approach using
this SNP.34 The success of using MR to infer causality
depends on the predictive utility of the variant, in add-
ition to the effect that smoking actually has on the
outcome of interest which is less clearly understood. We
have conducted an IPD meta-analysis of smoking and
physical and cognitive capability in ageing UK cohorts.
This is also the ﬁrst study to date to use the CHRNA5
rs16969968 variant to explore the causality of the rela-
tion between smoking and physical and cognitive cap-
ability. Although our results show that a larger sample
size is required, this approach has demonstrated that
MR analyses could be ‘instrumental’ in resolving the
smoking-ageing question.
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